daratumumab,pomalidomide,ciltacabtagene autoleucel,dexamethasone,bortezomib
janssen,Nanjing Legend Biotech
['cartitude', 'cilta-cel', 'mmsm', 'cartitude-4']
#eha2023 | shares results from the phase 3 cartitude-4 trial of cilta-cel vs soc in len-refractory mm. orr 99% with 86% cr and 72% mrd neg in cilta-cel as-treated group. #mmsm #myeloma 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma